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Previous studies showed that several members of the S100A family are involved in neovascularization and tumor development.
This study checked whether low concentrations of S100A8 or S100A9 has any eﬀect on the behaviour of vascular endothelial cells.
A human umbilical vascular endothelial cell (HUVEC) line was used to measure vascular endothelial cell bioactivity related to
angiogenesis, such as cell proliferation, migration, and vessel formation. In the low concentration range up to 10μg/mL, either
each alone or in combination, S100A8 and S100A9 proteins promoted proliferation of HUVEC cells in a dose-dependent manner.
The presence of both proteins in culture showed additive eﬀects over each single protein. Both proteins enhanced HUVEC cells
to migrate across the transwell membrane and to form tube-like structures on the Matrigel surface. When mixed in Matrigel and
injected subcutaneously in Balb/c mice, both proteins increased vessel development in the gel plugs. Microarray assay of HUVEC
cells treated with 10μg/mL S100A8 revealed that ribosome pathway, pathogenic Escherichia coli infection pathway, apoptosis, and
stress response genes were modulated by S100A8 treatment. We propose that S100A8 and S100A9 proteins from either inﬁltrating
inﬂammatory cells or tumor cells play an important role in the interplay among inﬂammation, angiogenesis, and tumorigenesis.
1.Introduction
While angiogenesis is fundamental to embryonic develop-
ment and regeneration of injured tissues, unwanted angio-
genesis, which is usually referred to as neovascularization, is
a common pathological process of diseases such as cancer,
autoimmune disorders, and transplant rejection. In recent
years, the triangular relationship among inﬂammation, an-
giogenesis, and tumor development in the ﬁelds of cancer
biology and immunology have been studied extensively, and
the most encouraging progress is the gradual uncovering
of the molecular mechanisms for inﬂammation-associated
tumorigenesis [1–5]. In brief, many of the key molecules or
pathways that are previously proven vital for inﬂammation
or immunity, such as Nod1 [6], IKKβ [7], SOCS3 [8],
nitric oxide [9], TLR-MyD88 pathway [10], epigenetics [11,
12], or even T-cell activation [13] are now shown to be
involved in inﬂammation-associated tumorigenesis, though
the very ﬁrst step at molecular level for inﬂammation-
induced neoplastic transformation is yet to be determined.
Once transformation succeeds and neoplatic cells appear,
the interplay between inﬂammation and tumor development
becomes more complex and dynamic in determining the fate
of the transformed cells [14, 15] ,a n ds o o n e ro rl a t e r ,a n o t h e r
player, namely, angiogenesis, will join. On one side, a large
number of cytokines, chemokines, or enzymes produced
by inﬂammatory cells modulate tumor cells growth or the
formation of blood vessels in tumor mass. On the other
side, tumor cells may secrete some molecules that attract
and modulate inﬂammatory cells. Thus it is feasible to
control tumors by targeting neovascularization [16, 17], or
by interfering the inﬂammation-tumor process [18] or the
inﬂammation-neovascularization crosstalk [19].
In a preliminary research project using chemical burn-
or suture-induced inﬂammatory corneal neovascularization
models, we identiﬁed two well-documented inﬂammation2 Mediators of Inﬂammation
mediators mainly produced by inﬁltrating neutrophils in
such models, namely, S100A8 and S100A9, as potential
promoters of neovascularization [20]. When looking into
the potential mechanisms for such activity of S100A8/A9,
we found that low concentrations of S100A8/A9 promoted
proliferation, migration, and tube formation of vascular
endothelial cells. Taking into account the fact that many
tumors produce S100A8/A9 to a certain extent [21–23],
we proposed that S100A8/A9, from either tumor cells or
inﬁltrating leukocytes, promote the transformed cells to
create a blood vessel supply for themselves.
2.MaterialsandMethods
2.1. Cell and Proliferation Assay. Human umbilical vascular
endothelial cells (HUVECs) were maintained in Dulbecco’s
modiﬁed Eagle’s medium (DMEM) supplemented with
10% heat-inactivated fetal bovine serum. Cell proliferation
was measured by using 3-(4,5-dimethyl-2-thiazolyl)-2,5-
diphenyl-2H-tetrazolium bromide (MTT) assay. In brief,
HUVEC were seeded in 96-well microplates at 5 ×
104 cells/100μL/well, cultured overnight in complete culture
medium, washed with and starved in serum-free DMEM for
6 hours, and then treated with recombinant low-endotoxin
grade human S100A8 or S100A9 (Cyclex Co. Ltd., Nagano,
Japan) at 0, 1, 5, and 10μg/mL in serum-free DMEM for 24
hours. Twenty microliters of 5mg/mL MTT reagent (Sigma,
St. Louis, MO) was added to each well, and the incubation
continued for another 4 hours. After removal of the medium
containing the MTT reagent, 150μL dimethyl sulfoxide were
added to each well. The plates were shaken for 10min before
reading by a MD2 microplate reader (Molecular Devices,
Sunnydale, CA) at a wavelength of 490nm.
2.2. Cell Migration Assay. Cell migration was assessed
by using transwell membrane inserts with 8.0μmp o r e s
(Corning, Acton, MA). Five hundred microliters of cul-
ture medium with or without S100A8 (10μg/mL), S100A9
(10μg/mL), or S100A8 + S100A9 protein (10μg/mL both)
were placed in the lower chambers, and 4 × 105 HUVEC in
200μL complete medium were added to the upper chamber.
The plate was incubated at 37◦C for 4 hours and the ﬁlters
were then removed for ﬁxation in methanol. Cells that
migrated to the lower surface of the ﬁlter were stained with
0.1% crystal violet and counted using a light microscope in
four random ﬁelds per well. The results are expressed as the
number of migrated cells per ﬁeld. Three inserts were set for
each group in this experiment.
2.3.InVitroCellVascularTubeFormationAssay. Invitrotube
formation assays was carried out according to previously
reported methods, with modiﬁcations. The wells of a 96-
well tissue culture plate were coated with 40μLo fi c e -
cold Growth Factor Reduced Matrigel (BD Bioscience, San
Jose, CA) at 37◦C for 1 hour. Twenty thousand HUVEC
in 200μL medium with or without S100A8, S100A9, or
S100A8 + S100A9 proteins were added to each well. After
incubation for 6 hours at 37◦Ci n5 %C O 2, the cultures were
photographed and the tube-like structures were evaluated.
2.4. In Vivo Matrigel Plug Angiogenesis Assay. The Matrigel
implantation assay was performed as outlined by McMahon
et al. [24]. In brief, 300μL of Matrigel supplemented
with S100A8, S100A9, or both to 10μg/mL were injected
subcutaneously into the ventral groin region of Balb/c
mice (Beijing Institute of Pharmacology, Beijing, China).
T h es a m ev o l u m eo fM a t r i g e la l o n e ,o rs u p p l e m e n t e d
with 200ng/mL ﬁbroblast growth factor (FGF) (R&D,
Minneapolis, MN) plus heparin (10U/mL), was used as
negative or positive controls, respectively. After 10 days,
Matrigel implants were isolated from the surrounding tis-
sues, washed with PBS, and photographed. Each specimen
was divided evenly into two pieces, one being ﬁxed for
routine histopathology, the other frozen and lyophilized
overnight. The dried Matrigel was weighed, rehydrated in
0.4mL of 0.1% Triton X-100 for 1 hour, disrupted by
vigorous pipetting, and centrifuged at 14,000×gf o r1 5m i n
to remove particulates. The concentration of hemoglobin in
the solution was determined by comparing the absorbance at
405nm to a standard curve made with puriﬁed hemoglobin
(Sigma). Use of animals was approved by the Shandong
Eye Institute Review Board with permit number SEIRB-
2009-2009CB526506 in accordance with the Guidelines on
the Humane Treatment of Laboratory Animals (Chinese
Ministry of Science and Technology, 2006) and the Associ-
ation for Research in Vision and Ophthalmology (ARVO)
Statement for the Use of Animals in Ophthalmic and Vision
Research.
2.5. Gene Proﬁling Using Microarray Assay. HUVECs were
seeded in six-well microplates at 6 × 104 cells/1.5mL/well.
S100A8 was added to 10μg/mL, and untreated wells were
included as control for S100A8 treatment, both in triplicates.
After 4 or 24 hours of culture, the cells were harvested
and total RNA was prepared by using QIAGEN RNeasy
Mini Kit (Qiagen Inc., Valencia, CA) as recommended by
the manufacturer. The integrity and high quality of RNA
samples were conﬁrmed by using agarose electrophoresis.
Two micrograms of RNA were reverse-transcribed to cDNA,
during which process a T7 sequence was introduced into
the cDNA. T7 RNA polymerase-driven RNA synthesis was
used for the preparation and labeling of cRNA with Cy3
(theS100A8-treatedsamples)andCy5(thecontrolsamples),
respectively. Equal amounts (875ng) of puriﬁed Cy3- and
Cy5-labelled probes were mixed and used for hybridisation
on one Agilent Human Oligo 4x44K Microarray (Agilent
Technologies Inc., Santa Clara, CA) following the protocol
provided by the manufacturer. This type of microarray cov-
ers41,000+uniquegenesandtranscripts.Threeindependent
pairs of samples for each time point were utilized on three
microarrays, respectively. The hybridization signals were
acquired by using an Agilent G2565BA Microarray Scan-
ner System and analyzed using Agilent G2567AA Feature
Extraction Software 10.0 (Agilent Technologies, Santa Clara,
CA) with default settings. Speciﬁcally, the Linear Lowes dyeMediators of Inﬂammation 3
method was used for normalization of the features. Based
on the global normalization, each feature was marked by the
analysis software as absent (A), marginal (M), or present (P).
To be counted as P, a feature has to pass four criteria, namely:
(1) it is positive and signiﬁcant versus the background,
(2) the signals are uniform in the spot, (3) the signals are
not saturated, and (4) there are no population outliers in
either channel. To minimise the risk of false positives when
evaluating the expression change, only those probes that
had one or less “A” and gave average signal densities above
200 for the three replicate arrays were subjected to further
analysis. The diﬀerentially expressed genes at the two time
points were annotated and compared using the Database for
Annotation,VisualizationandIntegratedDiscovery(DAVID,
v6.7) with the whole human genome as the background
[25]. The complete sets of raw and normalized data of
this microarray assay are deposited in the NCBI Gene Ex-
pression Omnibus (GEO) with the GEO accession number
GSE33768.
3. Results
3.1. S100A8 and S100A9 Promote HUVEC Proliferation.
When added separately to culture medium at 1, 5, and
10μg/mL, both S100A8 and S100A9 showed dose-dependent
stimulatory eﬀects on HUVEC proliferation. When both
S100A8 and S100A9 were present at 10μg / m L ,am o d e r -
ate additive eﬀect was noticed (Figure 1). This indicates
that, though S100A8 and S100A9 were proposed to form
heterodimers (S100A8/A9) under physiological conditions,
each of them alone also manifested biological activity on
HUVEC. In the following studies, we utilized 10μg/mL as a
representative concentration of both proteins.
3.2. S100A8 and S100A9 Stimulate Migration and Tube For-
mation of HUVEC. A transwell chamber system was em-
ployed to measure the eﬀect of S100A8 and S100A9 proteins
on endothelial cell migration or invasion. As shown in
Figure 2, S100A8, S100A9, or S100A8 + S100A9 increased
HUVEC migration across the transwell membrane. Sim-
ilarly, S100A8 and S100A9 proteins also promoted tube-
like structure formation of cultured HUVEC on Matrigel
(Figure 3). While S100A9 was less eﬀective than S100A8 in
both readouts, an additive eﬀect for S100A8 and S100A9 was
also observed.
3.3. S100A8 and S100A9 Proteins Promote Vascularization
In Vivo . Matrigel plug assay in vivo was used to assess
the proangiogenic activity of S100A8, S100A9, or S100A8
plus S100A9. On the tenth day after injection of Matrigel
premixed with the tested proteins, plugs were removed for
analysis. A representative implant for each treatment group
is shown in Figure 4. Gross examination of the plugs, he-
moglobin measurement, and histological study indicated
that S100A8, S100A9, or their combination signiﬁcantly
enhanced blood vessel formation in the plugs, but their
eﬀects at 10μg/mL were signiﬁcantly lower than that of
200ng/mL FGF plus 10U/mL heparin.
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Figure 1: Stimulation of HUVEC proliferation following S100A8
or S100A9 protein treatment at diﬀerent concentrations. Shown are
representatives of three experiments with similar results.
3.4. Ribosome Pathway and Pathogenic Escherichia coli Infec-
tion Pathway Were Modulated by S100A8 Treatment. Lastly,
we proﬁled the whole-genome gene expression patterns in
HUVEC to screen for the genes or pathways responsible for
the eﬀect of low concentrations of S100A8. After culture
in 10μg/mL S100A8 for 4 or 24 hours, 189 probes in
total were regulated by over 1.5-fold. Among these probes,
34 did not relate to any deﬁned genes, while the other
155 probes corresponded to 143 deﬁned genes in total
(Table S1 of the supplementary material available online
at doi:10.1155/2012/248574). While many genes showed a
concerted change (either upregulation or downregulation)
at both time points, no gene showed an opposite change at
these two time points (Tables S1 and S2). For those genes
having two or three probes in this array, the changes of
the probes were consistent with each other, such as with
metallothionein 2A (Table 1). This also reﬂects the reliability
and accuracy of the microarray results. DAVID analysis of
the changed genes revealed that ribosome pathway-related
genes were enriched over 30-fold in the downregulated
genes in both conditions (Table S3, Figure S1). Another
main pathway negatively modulated by S100A8 treatment
was pathogenic Escherichia coli infection (PECI) (Table S3).
In more detail, the four downregulated genes involved in
the PECI pathways at 4 hours were beta actin (ACTB,
NM 001101), gamma 1 actin (ACTG1, NM 001614), ker-
atin 18 (KRT18P19, NM 199187), and alpha 1c tubulin
(TUBA1C, NM 032704). The four genes downregulated at
24 hours were ACTB, ACTG1, KRT18P19, and beta 2C4 Mediators of Inﬂammation
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Figure 2: Photographs of HUVEC cells migrated through transwell chambers. The numbers above each panel are the cell counts per
microscope ﬁeld (mean ± standard deviation, n = 6).
∗P < 0.05 versus medium control by the two-tailed, paired Student’s t-test.
(a) (b)
(c) (d) (e)
Figure 3: Tube-like structure formation of HUVEC seeded on Matrigel with or without S100A8 or S100A9 protein in vitro (both at
10μg/mL). FGF plus heparin was used as a positive control.
tubulin (TUBB2C, NM 006088). Due to the limitation of
the available numbers of the upregulated genes, no pathways
were shown to be signiﬁcantly upregulated.
3.5. Apoptosis and Stress Response Genes Were Modulated
by S100A8 Treatment. Continuing along the ontology of
the altered genes, it was found that most of the enriched
GO terms are closely related with cellular metabolism, for
example, transcription, translation, apoptosis, ribosome bi-
ogenesis, and so on (Table S4). In terms of apoptosis, nine
genesweredownregulatedat4hoursafterS100A8treatment.
They were KRT18P19; lectin, galactoside-binding, soluble,
1 (LGALS1, NM 002305); nonmetastatic cells 1, protein
(NM23A) expressed in (NME1-NME2, and NM 198175);
nucleophosmin 1 (nucleolar phosphoprotein B23, numa-
trin) pseudogene 21 (Npm1, NM 006993); protein phos-
phatase 3 (formerly 2B), regulatory subunit B, alpha isoform
(Ppp3r1, NM 000945); ribosomal protein S3A pseudo-
gene 5 (RPS3AP5, XM 001719310); transmembrane pro-
tein 102 (Tmem102, NM 178518); ubiquitin B (UBB,
NM 018955); ubiquitin C (UBC, NM 021009). At 24 hours,
four apoptosis-related genes were downregulated, including
RPS3AP5, TUBB2C, UBB, and UBC. Several genes that were
of special interest are listed in Table 1. For example, S100A6
was downregulated by S100A8 treatment, while none of the
other members of the S100A family showed any change
(Table S5). On the contrary, none of the genes that were
reported to respond to high concentrations (200μg/mL) of
S100A8 in vascular endothelial cells [26, 27] showed any
signiﬁcant changes in this study (Table S6).
4. Discussions
We previously reported that neutralization of S100A8 using
speciﬁc monoclonal antibody inhibited vessel development
in experimental inﬂammatory corneal neovascularization
[20]. Now, by measuring the direct eﬀect of S100A8, and
S100A9 proteins on HUVEC, we showed that these two
proteins, when present at low concentrations, promote
angiogenesis. This is contrary to observations that high con-
centrations of S100A are pro-apoptotic to vascular endothe-
lial cells [26, 27]. Thus, the study described here extends
our knowledge about the interplay among inﬂammation,
angiogenesis, and tumorigenesis. While other members of
this family, such as S100A4 [28, 29], S100A7 [30]a n d
S100A13 [31], have been shown to participate under similarMediators of Inﬂammation 5
Table 1: Representative of changed genes upon S100A8 treatment.
Genbank accession Gene name 4hr 24hr
NM 005497 gap junction protein, gamma 1, 45kDa 1.724 ±0.307 0.971 ±0.089
NM 003714 stanniocalcin 2 1.453 ±0.014 1.507 ±0.168
NM 000584 interleukin 8 1.404 ±0.246 1.738 ±0.189
NM 002133 heme oxygenase (decycling) 1 1.686 ±0.425 1.881 ±0.266
NM 014624 S100 calcium binding protein A6 0.418 ±0.043 0.552 ±0.036
NM 002422 matrix metallopeptidase 3 0.952 ±0.094 1.557 ±0.104
NM 005950 metallothionein 1G 0.589 ±0.021 0.654 ±0.039
NM 005952 metallothionein 1X 0.690 ±0.033 0.789 ±0.044
NM 005953 metallothionein 2A 0.530 ±0.057 0.624 ±0.100
NM 005953 metallothionein 2A 0.421 ±0.054 0.492 ±0.058
NM 005953 metallothionein 2A 0.417 ±0.045 0.470 ±0.039
Hg(ug/mg)
1
2
8
4
Control
FGF/
heparin
S100A8
S100A9
S100A8 +
S100A9
(a) (b) (c)
(d) (e) (f)
Figure 4: Photographs (pictures, upper left panel), haemoglobin contents (solid columns, upper left panel), and histology of Matrigel plugs
indicating increased neovascularization following S100A8 or S100A9 protein treatment. Matrigel mixed with PBS was the negative control
group, and FGF plus heparin was the positive control group. Haemoglobin content of Matrigel plugs (mean ± standard deviation, n = 4)
was expressed as the amount of haemoglobin per gram of Matrigel plug. Microscopic examination of the same Matrigel plugs showed
inﬂammatory cells and vascular structures (arrowheads). Shown are representations of two experiments with similar results.
conditions, this discussion focuses on S100A8/A9’s role in
tumorigenesis by reviewing the eﬀects of S100A8/A9 on
tumorcellsorvascularendothelialcells.TableS7summarizes
the main reports concerning expression changes of S100A8,
S100A9, or S100A8/A9 in tumors versus normal correspond-
ing tissues. While most studies showed that S100A8/A9
is overexpressed in various types of cancers [23, 32, 33],
these proteins might also be underexpressed in some other
cancers [34]. As with the eﬀect of S100A8/A9 on cell growth,
apparently contradictory observations exist. Some in vitro
studies have demonstrated the apoptosis-inducing eﬀects of
S100A8/A9 in tumor cells [35, 36] .Ar e c e n ts t u d yd e m o n -
strated that low concentrations of S100A8/A9, namely, 5 or
10μg/mL, signiﬁcantly promoted tumor cell proliferation
of human breast cancers and human neuroblastoma cell
lines; when the concentration of S100A8/A9 was increased
to 25μg/mL, however, the promoting eﬀect disappeared
[37]. Interestingly enough, those authors showed that the
promotion eﬀect of low concentrations of S100A8/A9 on
tumor cells proliferation was mediated by the RAGE-NFκB
pathway, a pathway that was proposed in other studies to
mediate the pro-apoptotic eﬀect of S100A8/A9 [38, 39].
On the other hand, S100A8/A9 has long been known
to regulate vascular inﬂammation. To the best of our
knowledge, all existing reports proposed that S100A8/A9
serves as an injury signal for endothelial cells of the vascular6 Mediators of Inﬂammation
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Figure 5: Roles of S100A8/A9 in tumorigenesis. In this hypothesis, S100A8/A9 are produced by newly formed tumor cells or inﬁltrating
leukocytes. When they reach adequately low concentrations, they can stimulate (1) tumor cells proliferation, (2) vascular endothelial cell
proliferation, migration, and formation of vascular structures, and (3) neutrophils to migrate into tumor mass or adhere to endothelium.
By producing S100A8/A9, the newly entering neutrophils enhance local inﬂammation and neovascularization in turn. Other S100A family
members like S100A4, S100A7, and S100A13 may join S100A8 and/or S100A9 in this episode as well.
endothelium, mainly via promoting leukocyte recruitment
[40] and inducing proinﬂammatory responses in endothelial
cells [26, 27]. In a recent study using in vitro endothelial cells
cultureincombinationwitholigonucleotidemicroarraypro-
ﬁling, it was shown that treatment of human microvascular
endothelial cells with 200μg/mL heterodimeric S100A8/A9
resultedinanupregulationofseveralgenesthatareknownto
promote platelet aggregation, inﬂammation, and endothelial
permeability [27]. Interestingly, none of these genes showed
signiﬁcant change in our current study (Table S6). On
the contrary, our array assay suggested the metabolism-
related genes or pathways to be the main responders to
10μg/mL S100A8 treatment. Correspondingly, our study
is also the ﬁrst one to show that low concentrations of
S100A8 and S100A9, either alone or together, stimulate pro-
liferation, migration, and vascular formation of endothelial
cells.
This study is of signiﬁcance, since it proposes a new
explanation for why inﬂammation could be tumorigenic
or why small vascular-free tumor cell clusters develop
blood vessels and then keep on growing. We propose that
S100A8/A9, and perhaps also other S100A proteins, either
produced by tumor cells or by inﬁltrating inﬂammatory cells
[41], promote neovascularization in tumor mass by promot-
ing endothelial cells behavior (Figure 5). In this hypothesis,
especially at the early stage of cell transformation or
tumor formation, the S100A8/A9 produced from whatever
cells, start to accumulate locally and reach a range that
allow them to stimulate tumor cells or endothelial cells
proliferation, migration, and so forth, thus favor growth of
mass tumor. Our hypothesis partially explains why certain
chronic inﬂammation is tumorigenic, and why expression
of S100A8/A9 in tumors could be regarded as a prognostic
marker of several types of tumors [22, 42]. So far no data are
available with the levels of S100A8/A9 in tumor mass, but we
predict that their levels might never be high enough to cause
pro-apoptotic eﬀects on either tumor cells or endothelial
cells. This prediction was supported by several studies. For
example, in a study that proposed that serum S100A9 would
serve as a useful marker to discriminate between prostate
cancer and benign prostatic hyperplasia, the serum S100A9
concentration measured by ELISA was about 2–14ng/mL
in cancer patients [22]. The predicted enhancer eﬀect of
S100A8/A9 on tumor development was also conﬁrmed by a
couple of experimental studies. N´ emeth et al. reported that
increasing S100A8/A9 expression in mouse hepatocellular
carcinoma cells via transfection protected cells from death
and resulted in malignant progression [43]. Similarly, over-
expression of S100A8 in keratinocytes via adenoviral trans-
duction protected cells from irradiation-induced apoptosis
[44]. Considering the fact that other S100A family members
like S100A4, S100A7, and S100A13 are also involved inMediators of Inﬂammation 7
angiogenesis as well as inﬂammation, this hypothesis are
potentially applicable with the whole S100A family.
In conclusion, our results suggest that S100A8 and
S100A9 proteins at relatively low concentrations have the
potential to promote angiogenesis through directly enhanc-
ing proliferation, migration, and tube formation of vascular
endothelial cells. This ﬁnding not only provides a new
explanation for neovascularization development in situa-
tions of inﬂammation or tumor, but also suggests novel
targets during the management of related diseases such as
tumors. Future studies would investigate into the details of
production and action of these inﬂammation mediators in
thecontextoftheinterplaysbetweentumorcellsandvascular
endothelial cells.
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